ID   PPC-1
AC   CVCL_4778
SY   Primary Prostate Carcinoma-1; Specimen P-3
DR   BTO; BTO:0001062
DR   ATCC; HTB-190
DR   BioSample; SAMN03151895
DR   cancercelllines; CVCL_4778
DR   ChEMBL-Cells; CHEMBL3307780
DR   ChEMBL-Targets; CHEMBL1626502
DR   Cosmic; 948074
DR   GEO; GSM91929
DR   Progenetix; CVCL_4778
DR   PubChem_Cell_line; CVCL_4778
DR   Wikidata; Q54947777
RX   CelloPub=CLPUB00698;
RX   PubMed=2016798;
RX   PubMed=2583869;
RX   PubMed=8616865;
RX   PubMed=11304728;
RX   PubMed=12725112;
RX   PubMed=15486987;
RX   PubMed=20143388;
CC   Problematic cell line: Contaminated. Shown to be a PC-3 derivative (PubMed=11304728; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a 67 year old male patient with prostate carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00153.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ATCC; HTB-190; true.
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
ST   Source(s): ATCC=HTB-190; PubMed=11304728
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 14,15
ST   D21S11: 29,31.2
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 8,11
ST   D8S1179: 13
ST   FGA: 24
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 29
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
RX   PubMed=2016798; DOI=10.1016/S0022-5347(17)38540-3;
RA   Brothman A.R., Wilkins P.C., Sales E.W., Somers K.D.;
RT   "Metastatic properties of the human prostatic cell line, PPC-1, in
RT   athymic nude mice.";
RL   J. Urol. 145:1088-1091(1991).
RX   PubMed=2583869; DOI=10.1002/ijc.2910440525;
RA   Brothman A.R., Lesho L.J., Somers K.D., Wright G.L. Jr.,
RA   Merchant D.J.;
RT   "Phenotypic and cytogenetic characterization of a cell line derived
RT   from primary prostatic carcinoma.";
RL   Int. J. Cancer 44:898-903(1989).
RX   PubMed=8616865;
RA   Murakami Y.S., Albertsen H., Brothman A.R., Leach R.J., White R.L.;
RT   "Suppression of the malignant phenotype of human prostate cancer cell
RT   line PPC-1 by introduction of normal fragments of human chromosome
RT   10.";
RL   Cancer Res. 56:2157-2160(1996).
RX   PubMed=11304728; DOI=10.1002/pros.1045;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.;
RT   "Widely used prostate carcinoma cell lines share common origins.";
RL   Prostate 47:36-51(2001).
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
RX   PubMed=15486987; DOI=10.1002/pros.20158;
RA   Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R.,
RA   Brooks J.D.;
RT   "Genome-wide characterization of gene expression variations and DNA
RT   copy number changes in prostate cancer cell lines.";
RL   Prostate 63:187-197(2005).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).